Accurate diagnosis of metastatic castration-resistant prostate cancer (mCRPC) and assessment of biomarker status is crucial for identifying the most appropriate treatment in an ever-evolving therapeutic landscape. Join us for this on-demand video as a leading prostate cancer expert dives into evidence-based recommendations for biomarker testing, the latest evidence on targeted therapies in mCRPC, and special considerations for rural and underserved populations.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/expanding-community-oncology-competence-evidence-based-treatment-management
- Start Date: 2024-08-15 05:00:00
- End Date: 2024-08-15 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - Commercial Support: Source: Novartis Corporation Pharmaceuticals - Amount: 33333.33 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest